Core Viewpoint - Allogene Therapeutics reported a first-quarter 2025 loss of 28 cents per share, which aligns with the Zacks Consensus Estimate, showing an improvement from a loss of 38 cents per share in the same period last year [1] Financial Performance - The company did not report any sales during the quarter, as it lacks a marketed product, compared to collaboration revenues of $0.02 million in the year-ago period [1] - Research and development (R&D) expenses were $50.2 million, down 4% year over year, while general and administrative (G&A) expenses decreased by 13% to $15.0 million [5] - As of March 31, 2025, Allogene had $335.5 million in cash, cash equivalents, and investments, down from $373.1 million as of December 31, 2024 [5] 2025 Guidance - Allogene revised its 2025 guidance, expecting operating expenses to be around $230 million, including nearly $45 million in non-cash stock-based compensation, an improvement from the previous forecast of $250 million [6] - Cash burn for 2025 is now expected to be around $150 million, reduced from the previous guidance of $170 million, allowing the company to extend its cash runway into the second half of 2027 [7] Pipeline Updates - The pivotal phase II ALPHA3 study is evaluating lead drug cema-cel for treating newly diagnosed large B cell lymphoma patients, with the timeline for analysis pushed back to the first half of 2026 [9] - Allogene plans to initiate the phase I RESOLUTION basket study with ALLO-329 for autoimmune diseases in mid-2025, with the first data readout now expected in the first half of 2026 [10] - Updated data from the phase I TRAVERSE study evaluating ALLO-316 in advanced renal cell carcinoma will be presented at the 2025 ASCO Annual Meeting on June 1 [11] Stock Performance - Year to date, Allogene's shares have declined by 47%, contrasting with a 6% decline in the industry [2]

Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial .As we have all found out by now, the trade war that kept us all so busy over the past few weeks has shifted into a much lower gear, as talks between theAnalyst’s Disclosure: I/we have a beneficial long position in the shares of TPL, LB either through stock ownership, options, or ...

Generated record Q1 Contribution ex-TAC and programmatic revenue, driven by 40% year-over-year CTV revenue growth, alongside a 95% year-over-year increase in Adjusted EBITDA Trading structure simplification has driven higher trading volume as well as increased analyst and investor interest Completed $50 million Ordinary Share repurchase program and launched a new and ongoing $50 million repurchase program in April 2025 Hosting investor day on May 22, 2025 NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Nexxen ...

NORTHBOROUGH, Mass., May 14, 2025 /PRNewswire/ -- Aspen Aerogels, Inc. (NYSE: ASPN) ("Aspen" or the "Company"), a technology leader in sustainability and electrification solutions, today announced that the Company is scheduled to participate in the 25th Annual B. Riley Securities Investor Conference on Wednesday, May 21, 2025 and Thursday, May 22, 2025, to be held at the Ritz-Carlton in Marina Del Rey, CA.Donald R. Young, President & CEO, and Ricardo C. Rodriguez, CFO & Treasurer, will be hosting one-on-one ...

- Interim data from ENERGY 3 trial highlight INZ-701’s potential to modify disease course in ENPP1 Deficiency, with sustained phosphate increases and favorable safety and immunogenicity profile to date - - ENERGY 3 trial on track for topline data in first quarter of 2026; no patient dropouts, dose adjustments or discontinuations, and no new safety signals - - Petra Duda, M.D., Ph.D. appointed Chief Medical Officer - BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” ...

HALIFAX, Nova Scotia, May 14, 2025 (GLOBE NEWSWIRE) -- Erdene Resource Development Corp. (TSX:ERD; MSE:ERDN) ("Erdene" or the "Company") is pleased to announce operating and financial results for the quarter ended March 31, 2025, and to provide an update on progress at the Bayan Khundii Gold Project (“BK” or “Project”), being developed with Mongolian Mining Corporation (“MMC”). This release should be read in conjunction with the Company’s Q1 2025 Financial Statements and MD&A, available on the Company’s web ...

Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no interferon AB-101, oral small-molecule PD-L1 inhibitor, shown generally safe and well-tolerated with evidence of high receptor occupancy in Phase 1a/1b Andrew J. Sung joins Arbutus as General Counsel, bringing more than $28 billion in life sciences deal experience Strong financial position with cash, cash equivalents and marketable securities of $113M WARMINSTER, Pa., ...

Enrollment and dosing underway in Phase 3 clinical trial (the “MIRACLE” trial) evaluating Annamycin (naxtarubicin) for the treatment of R/R AML Regulatory and site selection progress to date supports interim data readout expected in the second half of 2025 Recently received European Medicines Agency (EMA) approval adds nine additional countries to the Company’s ongoing MIRACLE trial; Authorization granted in all EU countries requested Company to host conference call and webcast today, May 14th at 8:30 AM E ...

Disposition of stabilized asset reinforces long-term value creation strategyN. BETHESDA, Md., May 14, 2025 /PRNewswire/ -- Federal Realty Investment Trust (NYSE:FRT) today announced the sale of Levare, a 108-unit Class A residential building located within Santana Row in San Jose, California, for $74 million.Delivered in 2011, Levare has played a meaningful role in the evolution of Santana Row and reached a point in its lifecycle where Federal Realty could monetize its value and reallocate capital toward hi ...

VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- Stallion Uranium Corp. (the “Company” or “Stallion”) (TSX-V: STUD; OTCQB: STLNF; FSE: FE0) announces that the British Columbia Securities Commission (the "BCSC"), as the principal regulator of the Company, issued a cease trade order ("CTO") against the Company on May 7th, 2025 for the Company's failure to file its audited annual financial statements, accompanying management discussion and analysis and certifications for the financial year ended D ...